Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million

Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future

Fairmount Healthcare Fund II acquires Zenas BioPharma shares worth $3 million

Zenas BioPharma Raises Capital via Notes and Equity Offering

Zenas BioPharma director buys $1.5M in common stock

Zenas BioPharma director Hongbo Lu reports $1.5 million common share acquisition

Top Midday Decliners

Zenas BioPharma Tumble on Pricing of Convertible-Note, Stock Public Offerings

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Zenas Biopharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock With Aggregate Gross Proceeds of $300.0 Million

Stocks to Watch: Datacentrex, Unity Software, Veritone, Zenas BioPharma

BUZZ-Zenas BioPharma drops on convertible, equity offerings

Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing

Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis

Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target